Initial Announced Date: 2023-08-28 (August 28, 2025), Updated in 2023-12-18 (December 18, 2023)<\/p>\n\n\n\n
Asset: Three oncology discovery programs targeting RAS pathway-driven cancers<\/p>\n\n\n\n
Licensor: GenFleet Therapeutics (China)<\/p>\n\n\n\n
Licensee (Buyer): Verastem Oncology\u00a0(US)<\/p>\n\n\n\n
.<\/p>\n\n\n\n
Lead Program: GFH375\/VS-7375 (Announced in December 18, 2023)<\/p>\n\n\n\n
Asset Modality: Small molecule,\u00a0 orally<\/p>\n\n\n\n
Asset Target: KRAS G12D (ON\/OFF) inhibitor<\/p>\n\n\n\n
Potential Indication: Cancer<\/p>\n\n\n\n
Current Stage: PreClinical<\/p>\n\n\n\n
.<\/p>\n\n\n\n
Scope of Authority:<\/p>\n\n\n\n
The IND filing and initial Phase 1 studies will be led and funded by GenFleet in\u00a0China. <\/p>\n\n\n\n
The collaboration provides Verastem Oncology with an exclusive option to obtain a license to each of the three compounds in the collaboration after successful completion of pre-determined milestones in a Phase 1 trial. <\/p>\n\n\n\n
The licenses would give Verastem Oncology development and commercialization rights outside of\u00a0China while GenFleet would retain development and commercialization rights inside of\u00a0China.
.<\/p>\n\n\n\n
Payment Detail:<\/p>\n\n\n\n
The terms of the agreement include combined upfront, research support and option payments to GenFleet of\u00a0$11.5 million for the first program, <\/p>\n\n\n\n
with potential total deal size across all three programs up to\u00a0$625.5 million excluding royalties if Verastem Oncology exercises its in-license options. <\/p>\n\n\n\n
.<\/p>\n\n\n\n
Link:<\/p>\n\n\n\n
Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers | Verastem, Inc.<\/a><\/p>\n\n\n\n